Fig. 1 | Scientific Reports

Fig. 1

From: Novel dual action chimera doxorubizen demonstrates superior efficacy to doxorubicin in acute leukemia

Fig. 1

Synthesis and biological activity of doxorubizen. (A) Synthesis of doxorubizen and chimeras 1–7. (B) The cytotoxic effects of doxorubizen were compared to those of the parental drug Dox. BV-173, Granta, Jeko-1, KG-1a, and OCI-AML3 cells were treated with doxorubicin (dox) or doxorubizen for 48 h at 50 nM each. The proliferation rate was measured by the WST-1 assay. The graphs represent the means ± SEMs from at least 3 experiments; *p < 0.05. SEM: standard error of the mean; UT: untreated.

Back to article page